Research progress on the treatment of HR+/HER2-metastatic breast cancer at 2024 American Society of Clinical Oncology annual meeting
10.12354/j.issn.1000-8179.2024.20240963
- VernacularTitle:2024年ASCO年会HR+/HER2-晚期乳腺癌治疗研究进展
- Author:
Fang ZIRU
1
;
Zhou HUANHUAN
;
Wang XIAOJIA
Author Information
1. 浙江中医药大学 杭州市310053
- Publication Type:Journal Article
- Keywords:
breast cancer;
estrogen receptor;
hormonal receptor (HR);
cyclin-dependent kinase 4/6 inhibitor;
antibody-drug conjugates
- From:
Chinese Journal of Clinical Oncology
2024;51(22):1164-1169
- CountryChina
- Language:Chinese
-
Abstract:
The theme of the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting is "The art and science of cancer care:from comfort to cure." Extensive research was presented on the hormonal receptor (HR)-positive/human epidermal growth factor receptor 2 (HER2)-negative subtype of metastatic breast cancer. Three late-breaking abstracts (LBA) reported the latest findings of the post MONARCH (LBA1001),Young-PEARL (LBA1002),and SACI-IO HR+(LBA1004) studies,generating significant interest. In this paper,we present a compre-hensive review of the progress on HR+/HER2-metastatic breast cancer treatment research as reported at this annual meeting.
